Large data sets like SEER need better quality control checks and researchers and clinicians who use these data sets should also consider using secondary data analyses that answer specific research questions. This is the advice of a senior urologist following the removal of the PSA data.
A recent quality control check by the National Cancer institute (NCI) of the Surveillance, Epidemiology and End Results (SEER) and SEER-Medicare programs found that a significant number of these values were incorrect. Subsequently, NCI removed these PSA values from the data sets. A urologist at Vanderbilt University, David F. Penson, MD, MPH, has contributed an editorial in The Journal of Urology, which explores the ramifications of this elimination for research scientists, clinicians, and healthcare administrators who depend on these data sets to make healthcare decisions. Additionally, Dr Penson encourages researchers to collect primary data and create sub-group data sets to fill-in some of the data gaps that huge data sets like SEER have.
Read the report on ScienceDaily: http://bit.ly/1FreYVr
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen